GABBR2

GABBR2 encodes the GB2 subunit of the metabotropic GABA(B) receptor, which obligately heterodimerizes with GABBR1 (GB1) to form a functional G protein-coupled receptor that inhibits neuronal excitability through activation of GIRK potassium channels, inhibition of Ca²⁺ channels, and suppression of adenylyl cyclase/cAMP/PKA signaling via pertussis toxin-sensitive Gi/o proteins (PMID:9872315, PMID:10751439, PMID:41571204). Conditional knockout of Gabbr2 causes epileptiform activity, hyperlocomotion, hyperalgesia, impaired memory, and premature death, confirming its essential role in GABAergic inhibitory neurotransmission (PMID:41397015). De novo GABBR2 missense variants cause a spectrum of neurodevelopmental disorders: gain-of-function constitutive activity variants produce epileptic encephalopathy with adaptive downregulation of receptor and G protein signaling components, while loss-of-function variants are associated with Rett-like syndrome, ASD, and intellectual disability (PMID:28856709, PMID:40994051, PMID:41803176). GABBR2 transcription is regulated by androgen receptor promoter binding and by TAp73α-mediated displacement of the HDAC2/REST repressor complex, and its mRNA is post-transcriptionally repressed by miR-330 and HSV-1 latency-associated miR-H3/miR-H4 (PMID:37762034, PMID:40505831, PMID:32621101, PMID:37668872).

1. 1998 High

   Establishing obligate heterodimerization: demonstration that GABBR2 must partner with GABBR1 to form a functional GABA(B) receptor that activates GIRK channels resolved how the newly cloned subunit contributes to receptor signaling.

   Evidence Co-immunoprecipitation, co-localization, and GIRK channel electrophysiology in heterologous cells

   PMID:9872315

   Open questions at the time

   • Stoichiometry of the heterodimer not determined
   • Contribution of individual subunit domains to G protein coupling unknown
   • Native neuronal reconstitution not yet performed
2. 1999 Medium

   Revealing GABBR2 can independently couple to adenylyl cyclase inhibition suggested the subunit possesses intrinsic signaling capacity beyond heterodimerization, though this capacity is pharmacologically consistent with GABA(B) receptor function.

   Evidence Heterologous expression in CHO cells lacking GABBR1 with adenylyl cyclase assay and antagonist block

   PMID:10328880

   Open questions at the time

   • Relevance of homomeric GABBR2 signaling in native neurons not confirmed
   • Whether this activity occurs at physiological expression levels unknown
3. 2000 High

   Demonstrating that the GABBR1/GABBR2 heteromer is required for Ca²⁺ channel inhibition via Gi/o proteins in native neurons established the receptor's physiological effector coupling and pertussis toxin sensitivity.

   Evidence Antisense knockdown of GABBR1 and rescue by co-expression of both subunits in sympathetic neurons, with patch-clamp recording and pertussis toxin treatment

   PMID:10751439

   Open questions at the time

   • Whether GB2 directly contacts Gi/o or acts through GB1 not resolved
   • Structural basis of heterodimer-dependent G protein activation unknown
4. 2017 Medium

   Linking de novo GABBR2 variants to Rett-like syndrome and epileptic encephalopathy with graded loss-of-function severity established GABBR2 as a disease gene and showed that variant position determines phenotype.

   Evidence Whole-exome sequencing, heterologous cell functional assays, Xenopus tropicalis in vivo model, agonist rescue

   PMID:28856709

   Open questions at the time

   • Mechanism by which specific variant positions cause graded severity not structurally resolved
   • Long-term agonist rescue efficacy in mammals not tested
5. 2020 Medium

   Identifying miR-330 and the PKA/SynCAM1 pathway as regulators of GABBR2 expression and downstream signaling in pain models expanded understanding of post-transcriptional control and effector pathways beyond classical neuronal signaling.

   Evidence miR-330 mimic/inhibitor injection with luciferase 3'UTR assay (pain model); pharmacological epistasis in chronic migraine rat model

   PMID:32621101 PMID:32931071

   Open questions at the time

   • Direct miR-330 regulation of GABBR2 not confirmed in human neurons
   • PKA/SynCAM1 pathway linkage based on pharmacological epistasis without direct protein interaction data
6. 2021 Medium

   Discovery that GABBR2 promotes post-ischemic angiogenesis by supporting endothelial glycolysis revealed a non-neuronal function for the receptor.

   Evidence Lentiviral knockdown in HUVECs with metabolic flux analysis, and adenoviral overexpression in mouse hindlimb ischemia model

   PMID:34422926

   Open questions at the time

   • Whether the angiogenic role requires GABBR1 heterodimerization not tested
   • Mechanism linking GABBR2 to glycolytic enzyme expression unknown
   • Single lab finding
7. 2023 Medium

   Identifying AR-driven transcription and HSV-1 miRNA-mediated repression of GABBR2 defined transcriptional and viral post-transcriptional regulatory inputs controlling receptor abundance in disease contexts.

   Evidence ChIP showing AR binding to GABBR2 promoter with knockdown and antagonist validation in bladder cancer cells; luciferase 3'UTR assays confirming miR-H3/miR-H4 targeting

   PMID:37668872 PMID:37762034

   Open questions at the time

   • AR regulation of GABBR2 not examined in neurons
   • Physiological relevance of HSV-1 miRNA-mediated GABBR2 repression during latency in vivo not demonstrated
8. 2025 High

   Gain-of-function GABBR2 knock-in mice revealed that constitutive receptor activity triggers adaptive proteomic downregulation of GB1, GB2, and G protein components, explaining the paradoxical loss of agonist responsiveness in epileptic encephalopathy; positive allosteric modulator treatment normalized network activity.

   Evidence CRISPR knock-in mouse, EEG, slice electrophysiology, quantitative proteomics, pharmacological rescue with PAM

   PMID:40994051

   Open questions at the time

   • Molecular mechanism of adaptive receptor downregulation (transcriptional vs. degradative) not resolved
   • Long-term PAM efficacy and safety not assessed
9. 2025 High

   Conditional Gabbr2 knockout recapitulated the germline null phenotype — epilepsy, hyperalgesia, memory impairment, premature death — confirming cell-autonomous GABBR2 requirement and validating the floxed allele as a tool for circuit-specific studies.

   Evidence CRISPR-generated floxed Gabbr2 allele crossed with ubiquitous Cre, behavioral and histological phenotyping

   PMID:41397015

   Open questions at the time

   • Cell-type-specific contributions (excitatory vs. inhibitory neurons) not dissected
   • Whether phenotypes reflect developmental vs. acute loss not distinguished
10. 2025 Medium

    Demonstrating that TAp73α derepresses GABBR2 by displacing HDAC2/REST from its promoter, promoting EMT and invasiveness in melanoma, established a chromatin-level regulatory mechanism for GABBR2 in cancer.

    Evidence Multi-omics (transcriptomics, proteomics, cistromics), 3D protein interaction modeling, gain/loss-of-function in melanoma cells

    PMID:40505831

    Open questions at the time

    • Whether HDAC2/REST regulation of GABBR2 occurs in neurons not tested
    • Direct TAp73α binding to the GABBR2 promoter not shown by ChIP
11. 2026 Medium

    Functional characterization of NDD-associated GABBR2 variants revealed three distinct molecular mechanisms — constitutive activity, reduced GABA potency, and impaired surface trafficking — broadening the genotype-phenotype framework beyond the gain/loss-of-function dichotomy.

    Evidence Luciferase reporter and surface expression assays in heterologous cells for multiple de novo variants

    PMID:41803176

    Open questions at the time

    • Variant effects not validated in neuronal systems
    • Structural basis for trafficking-deficient variants not determined

• The structural basis for how GABBR2's transmembrane domain couples heterodimer-dependent conformational changes to selective G protein activation, and how gain-of-function mutations produce constitutive activity, remains unresolved at atomic resolution.
• No high-resolution structure of disease-mutant GABBR2 heterodimer in active state
• Cell-type-specific conditional knockout studies to map circuit-level functions not performed
• Whether non-neuronal GABBR2 functions require GABBR1 is untested